早期贝利尤单抗加速狼疮肾炎肾脏缓解并减少糖皮质激素暴露:多中心倾向匹配研究
该多中心倾向匹配研究比较了早期贝利尤单抗联合标准治疗与单用标准治疗在活检证实的狼疮肾炎患者中的肾脏缓解轨迹。结果显示,贝利尤单抗组6个月完全肾脏缓解率更高(35.9% vs 16.5%),达到完全肾脏缓解的时间更短,且缓解时糖皮质激素剂量更低。
要点
- 早期贝利尤单抗联合标准治疗可加速狼疮肾炎完全肾脏缓解
- 贝利尤单抗组达到缓解时糖皮质激素剂量更低
- 基线蛋白尿和贝利尤单抗使用是早期缓解的独立预测因素
核心结论
- 早期贝利尤单抗联合标准治疗加速完全肾脏缓解并减少糖皮质激素暴露,支持在狼疮肾炎管理中早期整合贝利尤单抗。
研究设计与样本
- 意大利狼疮转诊中心连续入组成人活检证实的狼疮肾炎患者,接受贝利尤单抗联合标准治疗作为初始治疗,与1990-2016年历史标准治疗队列比较。
- 基于基线蛋白尿、估算肾小球滤过率、标准初始治疗和组织学分类进行倾向评分匹配,得到可比组。
- 91例贝利尤单抗患者与91例标准治疗患者匹配。
主要发现
- 6个月时贝利尤单抗组完全肾脏缓解率更高(35.9% vs 16.5%,OR [95% CI]:2.81 [1.30, 6.29],P = 0.005)。
- 12个月时两组缓解率相似(P = 0.87)。
- 贝利尤单抗组达到完全肾脏缓解时间更短(中位 [四分位距] 5.64 [4.08, 7.80] vs 7.92 [5.28, 11.04] 个月,P < 0.01)。
- 达到完全肾脏缓解时,贝利尤单抗组糖皮质激素剂量更低(5 [5-15] vs 15 [10-20] mg/天,P = 0.018)。
- 更早完全肾脏缓解的独立预测因素为基线蛋白尿(每增加1 g/24 h的风险比 [95% CI]:0.89 [0.80, 0.98],P = 0.019)和贝利尤单抗使用(1.70 [1.11, 2.62],P = 0.016)。
关键数值与推荐
- 完全肾脏缓解按2019 EULAR/EDTA定义。
- 6个月完全肾脏缓解率:贝利尤单抗组35.9% vs 标准治疗组16.5%。
- 达到完全肾脏缓解中位时间:贝利尤单抗组5.64个月 vs 标准治疗组7.92个月。
- 达到完全肾脏缓解时糖皮质激素剂量:贝利尤单抗组5 mg/天 vs 标准治疗组15 mg/天。
临床怎么用
- 对活检证实的狼疮肾炎患者,可考虑早期联合贝利尤单抗与标准治疗以加速肾脏缓解并减少糖皮质激素暴露。
局限性
- 标准治疗对照组为1990-2016年历史队列,非同期随机对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: International guidelines recommend early combination of standard therapy with innovative agents in lupus nephritis (LN) to prevent kidney damage. Whether this accelerates renal response is unclear. We aimed to compare renal response trajectories, predictors and glucocorticoid (GC) burden in LN patients receiving early belimumab plus standard-of-care (SoC) vs SoC alone. METHODS: Consecutive adult patients with biopsy-proven LN treated with belimumab plus SoC as initial therapy were enrolled from Italian lupus referral centres and compared with a historical SoC cohort (1990-2016). Data were collected at baseline and during follow-up. Propensity score matching based on baseline proteinuria, estimated glomerular filtration rate, standard initial treatment and histological class led to comparable groups. Complete renal response (CRR) was defined per 2019 EULAR/EDTA. Cox regression was used to assess predictors. RESULTS: Ninety-one belimumab patients were matched to 91 SoC patients. At 6 months, CRR was higher in the belimumab group (35.9% vs 16.5%, odds ratio [95% CI]: 2.81 [1.30, 6.29], P = 0.005), while response rates at 12 months were similar (P = 0.87). Time-to-CRR was shorter with belimumab (median [interquartile range] 5.64 [4.08, 7.80] vs 7.92 [5.28, 11.04] months, P < 0.01). At CRR, GC dose was lower in the belimumab group (5 [5-15] vs 15 [10-20] mg/day, P = 0.018). Independent predictors of earlier CRR were baseline proteinuria (hazard ratio per g/24 h increase [95% CI]: 0.89 [0.80, 0.98], P = 0.019) and belimumab use (1.70 [1.11, 2.62], P = 0.016). CONCLUSION: Early belimumab combination therapy accelerates CRR and reduces GC exposure. Achieving early CRR with lower GC is a key target to limit kidney and GC-related damage, supporting early belimumab integration in LN management.
引用
- Gatto M, Cruciani C, Calatroni M, et al. Early belimumab accelerates renal response and reduces glucocorticoid exposure in lupus nephritis: a multicentre propensity-matched study. Rheumatology (Oxford). 2026. PMID: 42185215. doi:10.1093/rheumatology/keag269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。